真实世界中注射用矛头蝮蛇血凝酶在外科应用的药物经济学

目的评价注射用矛头蝮蛇血凝酶和注射用尖吻蝮蛇血凝酶应用于普外科和泌尿外科的疗效和经济学优势。方法通过回顾性数据库研究,获得注射用矛头蝮蛇血凝酶(巴曲亭■)和注射用尖吻蝮蛇血凝酶(苏灵■)的疗效和成本数据,以估计总失血量(e TBL)为主要疗效指标,并采用最小成本法进行经济学分析。结果巴曲亭组和苏灵组的e TBL分别为0.28 ml、0.31 ml,差异无统计学意义(P>0.05);巴曲亭组和苏灵组的每人均次药费分别155.59元、336.71元,差异有统计学意义(P<0.05)。结论注射用矛头蝮蛇血凝酶(巴曲亭■)应用于普外科和泌尿外科的经济性优于注射用尖吻蝮蛇血凝酶(苏灵■)。

Economic Evaluation of Hemocoagulase Bothrops Atrox for Injection for Surgery Application Based on the Real World

Objective To evaluate the therauputic effects and economic advantage of hemocoagulase bothrops atrox for injection and hemocoagulase agkistrodon for injection used in general surgery and urological surgery.Methods A retrospective database analysis was conducted to obtain the effectiveness and cost data of hemocoagulase bothrops atrox for injection(Baquting■)and hemocoagulase agkistrodon for injection(Suling■).The estimated total blood loss(eTBL)was used as the main therapeutic indexes,and economic analysis was performed using the cost minimization analysis.Results The e TBL of Baquting group and Suling group was 0.28 ml and 0.31 ml,respectively,and there was no statistical difference between the 2 groups(P>0.05).The average drug costs per patient of Baquting group and Suling group were￥155.59 and￥336.71,respectively,which was statistically significant(P<0.001).Conclusion Compared with hemocoagulase agkistrodon for injection(Suling■),hemocoagulase bothrops atrox for injection(Baquting■)has similar clinical effects in reducing blood loss during general surgery and urological surgery.